Kura Oncology, Inc. 8-K

What Happened

• On May 12, 2026, Kura Oncology, Inc. (KURA) announced its financial results for the quarter ended March 31, 2026 and provided a corporate update via a press release. The press release was furnished with the Form 8-K as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition). The filing also lists exhibits under Item 9.01. The report was signed by Teresa Bair, Chief Legal Officer.

Key Details

• Filing date: May 12, 2026.
• Reporting period: quarter ended March 31, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Form signed by Teresa Bair, Chief Legal Officer.

Why It Matters

• The 8-K notifies investors that Kura has released its quarterly earnings and a corporate update; those items can affect short-term share moves and provide information on revenue, R&D spending, cash runway, or clinical program progress.
• Retail investors should read the furnished press release (Exhibit 99.1) and the company’s subsequent SEC filings for the full financial figures and any management commentary or guidance disclosed there.